Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Cash flows from operating activities:
Net income	$ 1,179,802	$ 279,851
Adjustments to reconcile net income to net cash provided by operating activities:
Stock based compensation	598,699
Depreciation and amortization	$ 2,399	$ 4,167
Bad debt		3,000
Interest receivable		$ (3,164)
Deferred income tax	$ (857,000)
Increase (decrease) in cash flows as a result of changes in net assets and liabilities balances:
Accounts receivable	43,916	$ (188,935)
Inventories	(138,300)	(193,013)
Prepaid expenses and other current assets	(22,866)	(5,783)
Accounts payable	(28,362)	48,452
Customer deposit	9,240	86,284
Accrued expenses and other current liabilities	63,314	64,805
Due to shareholder	13,004	54,176
Total adjustments	(315,956)	(130,011)
Net cash provided by operating activities	$ 863,846	149,840
Cash flows from investing activities:
Investment in Angiodroid		(1,000)
Restricted cash	$ (437)	(173)
Net cash used in investing activities	(437)	(1,173)
Cash flows provided by (used in) financing activities:
Repayments on note payable - Bank	(19,000)	$ (9,024)
Sale of common stock	300,000
Net cash provided by (used in) in financing activities	281,000	$ (9,024)
Net increase in cash and cash equivalents	1,144,409	139,643
Cash and cash equivalents - beginning of year	216,395	83,156
Cash and cash equivalents - end of year	1,360,804	222,799
Cash paid for:
Interest	$ 2,054	$ 2,132